Breakthrough Therapeutics Targeting Brain Dysfunction
Enthorin Therapeutics is a clinical stage pharmaceutical company founded with the goal of developing innovative therapeutics that target brain circuit dysfunction to improve quality of life for patients, families, and communities.
Founders
Co-Founder
J. Guy Breitenbucher, Ph.D.
Former Head of Discovery Chemistry at Dart Neuroscience, and former Head of Pain Discovery Chemistry for Johnson & Johnson. Dr. Breitenbucher has 28 years of drug development experience.
Co-founder
Marco Peters, Ph.D.
Former Head of Neurobiology and Behavioral Pharmacology at Dart Neuroscience, and former VP and Head of Translational Science at Longboard Pharmaceuticals. With more than 20 years of industry R&D experience, Dr. Peters’ work has contributed to the discovery and development of therapeutics for a variety of CNS indications, including neurodevelopmental disorders, neurodegeneration, and epilepsy.
CO-FOUNDER
Michael A. Yassa, Ph.D.
Professor of Neurobiology, Neurology and Psychiatry at the University of California, Irvine and formerly Johns Hopkins University. Dr. Yassa is an expert in clinical neuroscience and biomarker development using advanced neuroimaging approaches and digital cognitive assessments.
Approach
Asset Pipeline
Enthorin recently entered into a $200M+ partnership with Mirum Pharmaceuticals for the clinical development of ENT-3379 for Fragile X. Read the Press Release here.
Clinical Indications
Fragile X syndrome (FXS) is the most common inherited intellectual and developmental disability (IDD). It is estimated to affect 38,000 - 87,000 individuals in the U.S. and 700,000-1.4M worldwide. Intellectual deficits include problems with memory, executive function, language, and visuospatial abilities. Behavioral anomalies include anxiety, autistic-like behavior, social and communication deficits. FXS is caused by silencing of the FMR1 gene, which reduces synaptic plasticity and memory function in the hippocampus and throughout the brain.
About 1 in 44 children are diagnosed with autism spectrum disorders (ASD). High unemployment, low participation in education, dependence on family in adulthood, and limitations in social interactions are common amongst those with ASD. No pharmacological treatments are available to improve cognitive function or improve language, sociability, and repetitive behaviors. Communication training and cognitive behavioral therapy are common behavioral interventions in ASD. The combination of behavioral interventions with cognitive enhancing (plasticity promoting) drugs could shift the treatment paradigm.
Parkinson’s disease (PD) affects more than 10 million people worldwide. Motor symptoms include uncontrollable movements, such as shaking, stiffness, and difficulty with balance and coordination. PD is linked to degeneration of the substantia nigra and its dopaminergic (DA) projections to the basal ganglia. Symptoms can be alleviated with DA-agents e.g., levodopa/carbidopa. Most PD patients develop L-DOPA induced Dyskinesia (PD-LID) as a result of long-term dopamine replacement therapy. PD is also associated with cognitive impairment and dementia, with no disease-modifying therapies available at this time.
Contact Us
For more information or to inquire about business development opportunities please contact Heidi Cervi